The FDA has approved the combination of nivolumab plus chemotherapy as first-line treatment for certain patients with stage III or IV classical Hodgkin lymphoma.The approval, for individuals aged 12 ...
Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results